Maze Therapeutics (MAZE) Operating Expenses (2024 - 2026)

Maze Therapeutics has disclosed Operating Expenses across 3 years of filings, most recently posting $46.6 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $46.6 million, up 31.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.1 million (up 31.33% YoY), and the FY2025 annual result was $142.9 million, up 30.01% from the prior year.
• Operating Expenses came in at $46.6 million for Q1 2026 at Maze Therapeutics, up from $38.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $46.6 million in Q1 2026 to a low of $25.4 million in Q2 2024.
• The 3-year median for Operating Expenses is $33.0 million (2025), against an average of $33.3 million.
• Peak annual rise in Operating Expenses reached 43.34% in 2025, while the deepest fall reached 23.33% in 2025.
• Maze Therapeutics' Operating Expenses stood at $29.7 million in 2024, then grew by 28.03% to $38.1 million in 2025, then climbed by 22.32% to $46.6 million in 2026.
• The last three Operating Expenses figures came in at $46.6 million (Q1 2026), $38.1 million (Q4 2025), and $33.0 million (Q3 2025), per Business Quant data.